Bharat Biotech has many products in the stage of clinical trials like malaria vaccine candidates, PvrII, rotavirus vaccine candidates, chikungunya vaccine and pandemic influenza vaccine.
Bharat Biotech International Ltd (BBIL) has achieved an annual turnover of Rs 126 crore and the company is expecting to touch Rs 300 crore in the year ahead. Established in the year 1996 by Dr Krishna M Ella and Suchitra K Ella, Bharat Biotech is engaged in developing next-generation vaccines and biotherapeutics through innovative and collaborative research.
It recently announced the encouraging results from a recent Phase I/II clinical trial of a live, natural reassortant, oral rotavirus vaccine 116E (ORV 116E), conducted in New Delhi, India.
Bharat Biotech has set new benchmarks in innovation and quality that epitomizes the tremendous progress of Indian biotechnology in the global arena. "We invest almost Rs 30-35 crore in a year in R&D. For the malaria vaccine and rotavirus program, we are supposed to be investing almost Rs 25 crore," said Dr Krishna M Ella, managing director, BBIL.
Bharat Biotech augmented the development of vaccines in the mid 1990s. The discovery and development of Revac-B, the world's first cesium chloride free recombinant hepatitis-B vaccine in 1998, offered Bharat Biotech's young business the opportunity to foster significant revenue potential in an area of high unmet need. The brand found instant acceptance in the country and is today one of the leading brands in its product category.
Bharat Biotech advanced its expertise further with the development of its second key product Biogit, India's first indigenously manufactured probiotic yeast. Biogit scored over other probiotics and existing Lactobacillus products with its own set of unique strengths. Bharat Biotech launched its second key vaccine - Typbar, a new generation typhoid vaccine in 2003 and then added another first to its growing list by introducing Zelect – Zinc with oral rehydration salts based on WHO approved formula. All these products experienced rapid uptake among the medical community and opened a new era of financial stability for Bharat Biotech.
The company became the first to develop and launch Indikinase in 2003-India's first recombinant streptokinase, the firstline therapy for myocardial infarction. Indikinase is poised to offer substantial market expansion opportunities for the mature recombinant streptokinase brand. In 2005, Bharat Biotech became the country's first biotechnology company to launch recombinant human Epidermal Growth Factor (rhEGF)-Regen-D. The company introduced Regen-D in two strengths; Regen-D 150 for diabetic foot ulcers and Regen-D 60 for I & II degree burns and conditions arising from donor site skin grafts.
Bharat Biotech has many products currently in the stage of clinical trials like malaria vaccine candidates, PvrII, rotavirus vaccine candidates, ORV116E, combination vaccine (Hepatitis-B+DPT+Hib), bioantibiotics, combination probiotics, chikungunya vaccine and pandemic influenza vaccine.